(Q43196497)

English

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population

scientific article published in January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

L Annemans

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

S Marbaix

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

K Webb

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

L Van Gaal

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

A Scheen

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

133-142

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.

1 reference

https://api.crossref.org/works/10.2165%2F11531910-000000000-00000

21 January 2018

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Understanding the determinants of health for people with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Revealing the cost of Type II diabetes in Europe.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20067331

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11531910-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43196497&oldid=1983608734"